OrbiMed’s HI-TECH PHARMACAL INC HITK Stock Holding History

OrbiMed’s Portfolio HITK Stock Details HITK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-371,200	Closed	-$12.3M	–	146
2013 Q2	$12.3M	Buy	+371,200	New	+$12.4M	0.26%	68

Other funds holding HITK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

OrbiMed's HITK Position: Q3 2013 in Review

OrbiMed sold out of HI-TECH PHARMACAL INC (HITK) in Q3 2013, closing a stake of 371,200 shares — an estimated $12.3M sold.

OrbiMed first reported a position in HITK in Q2 2013 and held it in 1 quarter. The position peaked at $12.3M in Q2 2013. 105 funds tracked by Wall St. Rank hold HITK as of Q3 2013.

OrbiMed reported no remaining HI-TECH PHARMACAL INC position as of Q3 2013 after selling out during the quarter.
OrbiMed sold 371,200 HI-TECH PHARMACAL INC shares in Q3 2013, an estimated $12.3M.
OrbiMed first reported a position in HI-TECH PHARMACAL INC in Q2 2013 and held it in 1 quarter.
OrbiMed's HI-TECH PHARMACAL INC position peaked at $12.3M in Q2 2013.
105 funds tracked by Wall St. Rank held HI-TECH PHARMACAL INC as of Q3 2013.

Based on OrbiMed's 13F filing for Q3 2013, filed 14 Nov 2013.